Clinical Trials Logo

Filter by:
NCT ID: NCT05887323 Active, not recruiting - Heart Failure Clinical Trials

LBBAP Data Collection Registry

Start date: April 25, 2023
Phase:
Study type: Observational

The purpose of this registry is to evaluate the safety and effectiveness of LBBA pacing/sensing in patients already implanted with the Tendril STS 2088 lead.

NCT ID: NCT05840185 Active, not recruiting - Myopia Clinical Trials

Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression (DAL)

Start date: August 10, 2023
Phase: N/A
Study type: Interventional

This is a mono-centre, prospective, one-arm, unmask clinical trial to evaluate the effectiveness of test lens in slowing myopia progression with respect to axial length elongation compared to a single vision spectacle lens from the historical control group of another clinical trial NCT05331378. A total of 40 children will be recruited

NCT ID: NCT05835557 Active, not recruiting - Clinical trials for Exercise Performance

Physiological Outcomes of High-intensity Interval Training With Post-exercise Blood Flow Restriction

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

This research study revolves around the physiological outcomes of using post-exercise blood flow restriction (BFR) with high intensity short interval training (ST) The main aims of this study are to compare (i) aerobic performance outcomes, and (ii) anaerobic and muscular performance outcomes - between 2 groups of participants after either undergoing 3 weeks of ST + post-exercise BFR (BFR-ST) or traditional ST.

NCT ID: NCT05827588 Active, not recruiting - Clinical trials for Chronic Kidney Diseases

Late Feasibility Study to Evaluate Safety and Efficacy of AWAK PD Device in Subjects With ESKD.

Start date: March 31, 2023
Phase: N/A
Study type: Interventional

The goal of this late feasibility clinical trial is to evaluate the safety and effectiveness of the Automated Wearable Artificial Kidney (AWAK) peritoneal dialysis (PD) device in subjects with end-stage kidney disease. The main questions it aims to answer are: - the success of AWAK PD therapies when used in a home-setting - the safety and effectiveness of the AWAK PD system Participants will: - be titrated to find a suitable AWAK PD prescription - be trained on how to use the AWAK PD system independently - use the AWAK PD system at home for at least 7 days

NCT ID: NCT05809934 Active, not recruiting - Clinical trials for Nonalcoholic Steatohepatitis

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

FORTUNA
Start date: March 15, 2023
Phase: Phase 2
Study type: Interventional

A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M Risk Allele

NCT ID: NCT05792449 Active, not recruiting - Clinical trials for Autism Spectrum Disorder

Tele-rehabilitation Program: An Innovative and Sustainable Early Intervention Service for Children With Autism Spectrum Disorders

Start date: January 7, 2019
Phase: N/A
Study type: Interventional

In Singapore, Autism Spectrum Disorders (ASD) is ranked number one in disease burden for children 0-14 years of age. The Child Development Unit at the National University Hospital serves 3000 children annually, of which 25-30% of children have been diagnosed with ASD. Therapist roles are to provide interim therapy for these children before entry into community-based Early Intervention Centres (EIPIC), which currently have waiting times of 6-9 months. Current limitations with interim care includes long wait times, high cost for families, lack of manpower and space to serve the patients, poor parental involvement due to their work commitments, parental difficulties attending frequent, needed, in-hospital therapy and difficulty generalizing patient treatment to the home/community setting (decreasing effectiveness). The proposed Telerehabilitation (also called Telerehab) initiative involves the use of video conferencing technology to help address the aforementioned deficits. Offering early intervention through Telerehab will enable previously unattainable benefits such as seeing the child in their home environment, allowing multiple caregivers to have access to the early intervention training, more frequent contact with families and the ability to trouble shoot real life difficulties in real time. The important advantages to the caregivers include less financial burden arising from time off from work and travel, more access to treatment over a longer period of time and ability to access a multidisciplinary team. An additional benefit for the children is they need not travel to unfamiliar environments, which is frequently distressing for children with ASD. Lastly, Telerehab is a sustainable initiative allowing for less manpower to cover the growing number of patients, and the possibility to be implemented in other government run hospitals and clinics facing similar challenges. Elaboration of benefits:1) Importance of parent and caregiver empowerment. Early Intervention in the current model has been predominantly centre based with initiatives to increase caregiver education. A large body of literature suggests that early intervention is highly successful when provided at the age of diagnosis, with younger children yielding better outcomes. Caregiver involvement is vital to long-term success, as they spend a significant amount of time with their child; they can support the generalizations of new skills. National Research Council identifies parent training to be the key component for successful intervention for children with autism. Parent training improves quality of life by reducing parental stress and increasing optimism.2) Addressing nationally identified gaps. The Enabling Master plan recommendations for 2012-2016 (under Ministry of Family and Social Development) identifies gaps in family involvement and support in acquiring necessary skills and knowledge to be competent in helping their children make developmental gains. Child Development Unit (CDU) envisions that Telerehab is a viable avenue for supporting parents in learning EI skills.3) Improving existing parent training programmes. CDU has successfully piloted a parent-training program for children with ASD called SPEECCH. In our study of the impact of this parent-training program, children made measurable progress in all four skill areas assessed (p<0.001). Focus on achievable and observable family- centred developmental goals showed evidence for increased parental understanding of children's learning and behaviour amp; effective use of strategies for facilitating communication and interactions to support their child's development (p<0.001). However this intervention service could not be sustained due to high caseload demands and insufficient manpower. Parent interviews during review visits identified having sustained contact with therapists and parent coaching to be key areas of need. Currently the service provides intervention for 24 children with ASD weekly for one hour across 12 weeks, and continued support for up to 20 weeks (maximum of 16 hours of intervention). Of the new referrals of 150 children with ASD, if a sustained service is to be provided, only a small group of children will receive intervention. In order to address the demand, the frequency and intensity of intervention has had to be sacrificed to be able to provide some service to all patients. Hence to maximize the impact of early intervention, a sustainable model of service delivery using technology through videoconferencing is being proposed.

NCT ID: NCT05782465 Active, not recruiting - Stomach Neoplasm Clinical Trials

Validation of a Molecular Test for Risk-stratification of Patients With High-risk Intestinal Metaplasia (GCEP2 Study)

Start date: August 23, 2019
Phase:
Study type: Observational

This study is carried out to find out if a customized molecular test can identify a subgroup of patients with very-high-risk of developing stomach cancer within patients with intestinal metaplasia (IM). The investigators hypothesise that the incidence of dysplasia and GC cases in the molecular-test-positive group will be significantly higher than that in the molecular-test-negative group. Such a test has the potential to guide clinicians to better manage patients with IM by allowing endoscopic surveillance to be focused on individuals at very-high-risk of developing stomach cancer, at the same time avoiding or reducing endoscopies for those at lower risk.

NCT ID: NCT05780437 Active, not recruiting - COVID-19 Clinical Trials

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Start date: February 5, 2021
Phase: Phase 3
Study type: Interventional

This study looks at the safety and effectiveness of AZD7442 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a AZD7442 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO Treatment Trial H4.

NCT ID: NCT05765448 Active, not recruiting - Nutrition, Healthy Clinical Trials

Effects of the Consumption of SEAweed Biomass Versus PROtein Isolates on Postprandial Satiety and Metabolism

SEAPRO
Start date: February 20, 2023
Phase: N/A
Study type: Interventional

There is a need to identify alternative sources of protein that can be introduced into diets to effectively meet the protein requirements of the population. Seaweed presents a potential source of sustainable, alternative protein. In order to determine their utility in future foods, in this study we will undertake an acute postprandial trial to explore whether a macroalgae (porphyra) and a microalgae (chlorella) protein isolates are more beneficial for acute metabolic health as compared to their respective whole biomasses. In particular, we will compare the effects of whole biomasses and their protein isolates on acute glucose homeostasis, amino acid availability as well as on satiety and gut hormones.

NCT ID: NCT05762016 Active, not recruiting - Breast Infection Clinical Trials

Outcomes of a Novel Technique of Mini- Incision and Self-Express (MISE) for Breast Abscess

Start date: January 1, 2018
Phase:
Study type: Observational

Conventional techniques for treatment of breast abscess, such as incision and drainage/percutaneous drainage, have disadvantages. Bedside Mini-Incision and Self-Express (MISE) is a novel technique for breast abscess. The outcomes of MISE were compared to the conventional techniques.